FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1545-1547 May 17, 2001 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Shirali, G. S. PubMed Citation

The question of a viral contribution to allograft dysfunction after solid-organ transplantation has long been debated. This debate has focused primarily on cytomegalovirus, which has been identified as a risk factor for bronchiolitis obliterans in lung-transplant recipients¹ and may be associated with a variety of forms of chronic allograft dysfunction in other solid-organ transplants. There is considerable evidence, but still some controversy, concerning the role of cytomegalovirus in cardiac-allograft vasculopathy, one of the primary conditions limiting survival in cardiac-transplant recipients.² Recent reports have raised the possibility that human herpesvirus 6 (HHV-6) infection may also be associated with allograft dysfunction.³

In . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sorensen, K., Hummel, M., Lind, J. M., Abeywickrama, K. H., Bernhardt, P., the RAD B253 Study Group, (2003). Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. NEJM 349: 847-858 [Abstract] [Full Text]  
• Mancini, D., Pinney, S., Burkhoff, D., LaManca, J., Itescu, S., Burke, E., Edwards, N., Oz, M., Marks, A. R. (2003). Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy. Circulation 108: 48-53 [Abstract] [Full Text]